Dietrich A. Stephan Ph.D.
Net Worth

Last updated:

What is Dietrich A. Stephan Ph.D. net worth?

The estimated net worth of Dr. Dietrich A. Stephan Ph.D. is at least $3,569,150 as of 2 Aug 2023. He has received compensation worth at least $3,569,150 in NeuBase Therapeutics, Inc..

What is the salary of Dietrich A. Stephan Ph.D.?

Dr. Dietrich A. Stephan Ph.D. salary is $713,830 per year as Founder, Pres, Chief Executive Officer, Chairman & Interim Chief Financial Officer in NeuBase Therapeutics, Inc..

How old is Dietrich A. Stephan Ph.D.?

Dr. Dietrich A. Stephan Ph.D. is 56 years old, born in 1969.

What stocks does Dietrich A. Stephan Ph.D. currently own?

As insider, Dr. Dietrich A. Stephan Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
NeuBase Therapeutics, Inc. (NBSE) Founder, Pres, Chief Executive Officer, Chairman & Interim Chief Financial Officer 24,525 $0 $0

What does NeuBase Therapeutics, Inc. do?

NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1; NT0300, a PATrOL-enabled therapeutic treatment to target the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

NBSE logo
NBSE
NeuBase Therapeutics, Inc.

Dietrich A. Stephan Ph.D. insider trading

NeuBase Therapeutics, Inc.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 93,234 $0.02 $2,051
Option
Stock option (right to buy) 93,234 $0.02 $2,051
Option
Common Stock 655,000 N/A N/A
Option
Stock option (right to buy) 655,000 N/A N/A
Option
Stock option (right to buy) 750,000 $0 $750
Option
Common Stock 750,000 $0 $750
Option
Common Stock 42,250 $0 $42
Option
Stock option (right to buy) 42,250 $0 $42
Purchase
Common Stock 12,000 $5 $60,000
Purchase
Common Stock 1,275 N/A N/A
Purchase
Common Stock 1,250 N/A N/A
Purchase
Common Stock 10,000 N/A N/A

NeuBase Therapeutics key executives

NeuBase Therapeutics, Inc. executives and other stock owners filed with the SEC:

  • Dr. Dietrich A. Stephan Ph.D. (56) Founder, Pres, Chief Executive Officer, Chairman & Interim Chief Financial Officer
  • Dr. William Roland Mann MBA, Ph.D. (65) Chief Operating Officer